Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 345

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Reviews Of Anti‐infective Agents: Liposomal Amphotericin B for the Treatment of Visceral Leishmaniasis

Bern, Caryn, Adler‐Moore, Jill, Berenguer, Juan, Boelaert, Marleen, Boer, Margriet den, Davidson, Robert N., Figueras, Concepcion, Gradoni, Luigi, Kafetzis, Dimitris A., Ritmeijer, Koert, Rosenthal, Eric, Royce, Catherine, Russo, Rosario, Sundar, Shyam, Alvar, Jorge·2006·Clinical Infectious Diseases

Abstract

During the past decade, liposomal amphotericin B has been used with increasing frequency to treat visceral leishmaniasis (VL). The World Health Organization convened a workshop to review current knowledge and to develop guidelines for liposomal amphotericin B use for VL. In Europe, liposomal amphotericin B is widely used to treat VL. In Africa and Asia, the VL disease burden is high and drug access is poor; liposomal amphotericin B is available only through preferential pricing for nonprofit groups in East Africa. Clinical trials and experience demonstrate high efficacy and low toxicity for liposomal amphotericin B (total dose, 20 mg/kg) in immunocompetent patients with VL. Combination trials in areas with antileishmanial drug resistance, and treatment and secondary prophylaxis trials in VL-human immunodeficiency virus-coinfected patients, are important to safeguard the current armamentarium and to optimize regimens. The public health community should work to broaden access to preferential liposomal amphotericin B pricing by public sector VL treatment programs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1086/507530

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 345

Metadata

Authors
Bern, C., Adler‐Moore, J., Berenguer, J., Boelaert, M., Boer, M. D., Davidson, R. N., Figueras, C., Gradoni, L., Kafetzis, D. A., Ritmeijer, K., Rosenthal, E., Royce, C., Russo, R., Sundar, S., & Alvar, J.
Venue
Clinical Infectious Diseases
Published
2006-10
Volume
43
Issue
7
Pages
917-924
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W2143697569
Cited by
345
References
33
FWCI
10.25
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reviews Of Anti‐infective Agents: Liposomal Amphotericin B for the Treatment of Visceral Leishmaniasis. https://app.cochat.ai/papers/10.1086/507530
The paper
Bern, C., Adler‐Moore, J., Berenguer, J., Boelaert, M., Boer, M. D., Davidson, R. N., Figueras, C., Gradoni, L., Kafetzis, D. A., Ritmeijer, K., Rosenthal, E., Royce, C., Russo, R., Sundar, S., & Alvar, J. (2006). Reviews Of Anti‐infective Agents: Liposomal Amphotericin B for the Treatment of Visceral Leishmaniasis. Clinical Infectious Diseases. https://doi.org/10.1086/507530

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.